Patents by Inventor Tony Durst

Tony Durst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150272922
    Abstract: A method for reducing glucocorticoids in an animal in need thereof comprising the use of compounds of the formula (I), wherein the definitions for R?, R1-R11 and n are as disclosed in the description.
    Type: Application
    Filed: November 8, 2013
    Publication date: October 1, 2015
    Inventors: Tony Durst, Zulfiquar Merali, Christian Cayer, John Thor Arnason, John Douglas Baker
  • Patent number: 8952073
    Abstract: The presently disclosed and claimed inventive concept(s) provides new estrogenic compounds of the general formula and pharmaceutical compositions containing them. The compounds of the presently disclosed and claimed inventive concept(s) are useful, for example, in hormone replacement therapies (HRT/ERT), and as contraceptives, and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the presently disclosed and claimed inventive concept(s).
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 10, 2015
    Assignee: University of Ottawa
    Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim, Christine Pratt
  • Publication number: 20150005267
    Abstract: Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Inventors: Tony Durst, Zulifiquar Merali, John T. Arnason, E. Pablo Sanchez-Vindas, Luis J. Poveda-Alvarez
  • Patent number: 8623848
    Abstract: Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: January 7, 2014
    Assignee: University of Ottawa
    Inventors: Tony Durst, Zulfiquar Merali, John T. Arnason, E. Pablo Sanchez-Vindas, Luis J. Poveda Alvarez
  • Publication number: 20130274344
    Abstract: The presently disclosed and claimed inventive concept(s) provides new estrogenic compounds of the general formula and pharmaceutical compositions containing them. The compounds of the presently disclosed and claimed inventive concept(s) are useful, for example, in hormone replacement therapies (HRT/ERT), and as contraceptives, and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the presently disclosed and claimed inventive concept(s).
    Type: Application
    Filed: June 7, 2013
    Publication date: October 17, 2013
    Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim, Christine Pratt
  • Patent number: 8471073
    Abstract: The present invention provides new estrogenic compounds of the general formula in which the substituents have the meanings that are explained in more detail in the description, and pharmaceutical compositions containing them. The compounds of the invention are useful, for example, in hormone replacement therapies (HRT/ERT) and as contraceptives and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the invention.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: June 25, 2013
    Assignee: University of Ottawa
    Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim
  • Publication number: 20130012477
    Abstract: Derivatives of dillapiol, sesamol and related monolignans having the following general formula: These compounds have synergistic properties, inhibit cytochrome P450 enzymes such as human CYP3A4, and can be used as pesticide synergists or pharmaco-enhancers. Accordingly, methods for increasing the efficacy and/or bioavailability of a pharmaceutically active agent and for increasing the potency of a pesticide are described, as are synergistic pesticidal and pharmaceutical compositions.
    Type: Application
    Filed: May 11, 2012
    Publication date: January 10, 2013
    Applicants: HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF HEALTH, UNIVERSITY OF OTTAWA
    Inventors: John Thor Arnason, Tony Durst, Brian Foster
  • Publication number: 20120190898
    Abstract: The present invention provides new estrogenic compounds of the general formula in which the substituents have the meanings that are explained in more detail in the description, and pharmaceutical compositions containing them. The compounds of the invention are useful, for example, in hormone replacement therapies (HRT/ERT) and as contraceptives and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the invention.
    Type: Application
    Filed: March 27, 2012
    Publication date: July 26, 2012
    Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim
  • Patent number: 8158684
    Abstract: The present invention provides new estrogenic compounds of the general formula in which the substituents have the meanings that are explained in more detail in the description, and pharmaceutical compositions containing them. The compounds of the invention are useful, for example, in hormone replacement therapies (HRT/ERT) and as contraceptives and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the invention.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: April 17, 2012
    Assignee: University of Ottawa
    Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim
  • Publication number: 20110196045
    Abstract: The present invention provides new estrogenic compounds of the general formula in which the substituents have the meanings that are explained in more detail in the description, and pharmaceutical compositions containing them. The compounds of the invention are useful, for example, in hormone replacement therapies (HRT/ERT) and as contraceptives and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the invention.
    Type: Application
    Filed: April 21, 2011
    Publication date: August 11, 2011
    Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim
  • Publication number: 20090234024
    Abstract: The present invention provides new estrogenic compounds of the general formula in which the substituents have the meanings that are explained in more detail in the description, and pharmaceutical compositions containing them. The compounds of the invention are useful, for example, in hormone replacement therapies (HRT/ERT) and as contraceptives and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the invention.
    Type: Application
    Filed: February 4, 2009
    Publication date: September 17, 2009
    Inventors: Hooman Shadnia, James S. Wright, Tony Durst, Muhammad Asim
  • Publication number: 20090143350
    Abstract: Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.
    Type: Application
    Filed: February 6, 2009
    Publication date: June 4, 2009
    Inventors: Tony Durst, Zulfiquar Merali, John T. Arnason, E. Pablo Sanchez-Vindas, Luis J. Poveda Alvarez
  • Patent number: 7488722
    Abstract: Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: February 10, 2009
    Assignee: University of Ottawa
    Inventors: Tony Durst, Zulfiquar Merali, John T. Arnason, E. Pablo Sanchez-Vindas, Luis J. Poveda Alvarez
  • Publication number: 20040235805
    Abstract: Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.
    Type: Application
    Filed: May 17, 2004
    Publication date: November 25, 2004
    Inventors: Tony Durst, Zulfiquar Merali, John T Arnason, E.Pablo Sanchez-Vindas, Luis J Poveda Alvarez
  • Publication number: 20040102514
    Abstract: Multi-ring organic compounds useful in compositions and methods for regulating gut motility to modulate food intake and treat obesity and malnutrition are described.
    Type: Application
    Filed: December 5, 2003
    Publication date: May 27, 2004
    Inventors: Anthony Krantis, Tony Durst
  • Patent number: 4567253
    Abstract: One aspect of this invention relates to 2-substituted podophyllotoxin corresponding to the formula: ##STR1## where R.sub.1 is the residue of an electrophile reactant with the precursor enolate, e.g., halogen, i.e., Br, Cl, F and I, lower alkyl (preferably methyl), hydroxyl, --SR.sub.5 where R.sub.5 is lower alkyl, aralkyl or aryl and COOR.sub.6 where R.sub.6 is hydrogen or lower alkyl. Another aspect of this invention relates to 2-substituted etopsides and related compounds corresponding to the formula: ##STR2## where R.sub.1 is as defined above, and where R.sub.2 is: ##STR3## where AcO is acetyl; or ##STR4## where R.sub.3 is hydrogen and R.sub.4 is alkyl, alkenyl, cycloalkyl, 2-furyl, 2-thienyl, aryl, aralkyl, or alkenyl wherein the aromatic ring (preferably phenyl) may be optionally substituted by one or more hydroxyl, alkyl, alkoxy, nitro or halogen; or where each of R.sub.3 and R.sub.4 is alkyl or where each of R.sub.3 and R.sub.
    Type: Grant
    Filed: February 3, 1984
    Date of Patent: January 28, 1986
    Inventors: Tony Durst, Margaret B. Glinski-Oomen, James C. Freed